Russell Investments Group Ltd. Raises Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Russell Investments Group Ltd. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 96.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,381 shares of the biopharmaceutical company’s stock after purchasing an additional 1,169 shares during the period. Russell Investments Group Ltd.’s holdings in Dynavax Technologies were worth $30,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVAX. Smartleaf Asset Management LLC raised its position in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies in the fourth quarter worth $71,000. Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in Dynavax Technologies during the 3rd quarter valued at $89,000. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DVAX shares. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group reduced their price target on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research note on Thursday, April 17th.

Dynavax Technologies Price Performance

DVAX opened at $10.82 on Monday. The company’s 50-day simple moving average is $12.78 and its two-hundred day simple moving average is $12.58. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63. The stock has a market capitalization of $1.32 billion, a P/E ratio of 60.11 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. As a group, analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.